Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

Metal based drugs: from serendipity to design.

Fricker SP.

Dalton Trans. 2007 Nov 21;(43):4903-17. Review.

PMID:
17992275
2.

Cysteine proteases as targets for metal-based drugs.

Fricker SP.

Metallomics. 2010 Jun;2(6):366-77. doi: 10.1039/b924677k. Review.

PMID:
21072382
3.

Carbohydrate-metal complexes and their potential as anticancer agents.

Hartinger CG, Nazarov AA, Ashraf SM, Dyson PJ, Keppler BK.

Curr Med Chem. 2008;15(25):2574-91. Review.

PMID:
18855680
4.

A categorization of metal anticancer compounds based on their mode of action.

Gianferrara T, Bratsos I, Alessio E.

Dalton Trans. 2009 Oct 7;(37):7588-98. doi: 10.1039/b905798f. Review.

PMID:
19759927
5.

Recent insights on the medicinal chemistry of metal-based compounds: hints for the successful drug design.

Hernandes MZ, de S Pontes FJ, Coelho LC, Moreira DR, Pereira VR, Leite AC.

Curr Med Chem. 2010;17(31):3739-50. Review.

PMID:
20846108
6.

Platinum group antitumor chemistry: design and development of new anticancer drugs complementary to cisplatin.

Abu-Surrah AS, Kettunen M.

Curr Med Chem. 2006;13(11):1337-57. Review.

PMID:
16712474
7.

Development and current status of unconventional platinum anticancer complexes.

Abu-Surrah AS.

Mini Rev Med Chem. 2007 Feb;7(2):203-11. Review.

PMID:
17305594
8.

Recent developments in the field of tumor-inhibiting metal complexes.

Galanski M, Arion VB, Jakupec MA, Keppler BK.

Curr Pharm Des. 2003;9(25):2078-89. Review.

PMID:
14529417
9.

Targeting cancer: the challenges and successes of structure-based drug design against the human purinome.

Knapp M, Bellamacina C, Murray JM, Bussiere DE.

Curr Top Med Chem. 2006;6(11):1129-59. Review.

PMID:
16842151
10.

Potential therapeutic applications of metal compounds directed towards hypoxic tissues.

Gambino D.

Curr Med Chem. 2010;17(31):3616-31. Review.

PMID:
20846115
11.

Enzyme inhibition as a key target for the development of novel metal-based anti-cancer therapeutics.

Griffith D, Parker JP, Marmion CJ.

Anticancer Agents Med Chem. 2010 Jun;10(5):354-70. Review.

PMID:
20380633
12.

Anticancer drug discovery and pharmaceutical chemistry: a history.

Braña MF, Sánchez-Migallón A.

Clin Transl Oncol. 2006 Oct;8(10):717-28. Review.

PMID:
17074670
13.

Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs.

Sava G, Jaouen G, Hillard EA, Bergamo A.

Dalton Trans. 2012 Jul 21;41(27):8226-34. doi: 10.1039/c2dt30075c. Review.

PMID:
22614531
14.

Lanthanides as anticancer agents.

Kostova I.

Curr Med Chem Anticancer Agents. 2005 Nov;5(6):591-602. Review.

PMID:
16305481
15.

Cytochrome P450s in the development of target-based anticancer drugs.

Purnapatre K, Khattar SK, Saini KS.

Cancer Lett. 2008 Jan 18;259(1):1-15. Review.

PMID:
18053638
16.

Novel metals and metal complexes as platforms for cancer therapy.

Frezza M, Hindo S, Chen D, Davenport A, Schmitt S, Tomco D, Dou QP.

Curr Pharm Des. 2010 Jun;16(16):1813-25. Review.

17.
18.

Ruthenium complexes as anticancer agents.

Kostova I.

Curr Med Chem. 2006;13(9):1085-107. Review.

PMID:
16611086
19.

Chemical approaches to the discovery and development of cancer therapies.

Neidle S, Thurston DE.

Nat Rev Cancer. 2005 Apr;5(4):285-96. Review.

PMID:
15803155
20.

Exploring biologically relevant chemical space with metal complexes.

Meggers E.

Curr Opin Chem Biol. 2007 Jun;11(3):287-92. Review.

PMID:
17548234

Supplemental Content

Support Center